Encouraging H1 numbers from Somero

Encouraging H1 numbers from Somero today. Turnover rose 12% to $39.7m. This not the standout top line growth that we have come to expect from this company over the past 5 years, but it is still v good compared to most other companies as its all organic. Standout performers were N America, which is c70% sales, rising 24%. Europe, China and Australia were also strong. Korea was v weak as was LATAM. Luckily the 2 largest geographies N America and China have made up for weakness in other areas. One must be mindful that a US slowdown would really hurt Somero.

The good news is that despite weaker trend growth (ie positive, but less positive than previously) margins have still expanded. GMs were 56% vs 55% driven by price increases. While EBIT margins increased to 26% from 23.5%, despite investment in selling expenses and people. So that's positive.

Diluted EPS was 12c vs 9c. The interim dividend has been raised 32% to 2.5c

The balance sheet remains in decent shape with $11.1m of net cash, but I don't expect this to be utilised much as management's mind is still fresh with the horrific commercial downturn of 2006-09. In a cyclical business such as this they recognise the value of cash on the B/S.

The outlook is fairly pragmatic expecting further profit growth this year driven by backlogs at their customers in N America. Management expects some recovery in international markets like Korea and the Middle East and a meaningful recovery in LATAM in H2.

Looking at numbers- revenue was split 50:50 in h1 : h2 last year and profits fractionally stronger in h2. If we therefore just double the h1 number (in an effort to be conservative) that would mean c24c of diluted EPS. This would translate into c18p of EPS and mean a PE of 9x. Given growth remains ok, I think this share has space to rerate marginally from here, although I expect most of the price appreciation to be driven by any further EPS growth in 2017. Looks ok for now. I remain a holder.

As usual please DYOR.

Unlock the rest of this article with a 14 day trial

Already have an account?
Login here